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Background. The effects of antidepressants for treating depressive disorders have been overestimated because of
selective publication of positive trials. Reanalyses that include unpublished trials have yielded reduced effect sizes.
This in turn has led to claims that antidepressants have clinically insigniﬁcant advantages over placebo and that
psychotherapy is therefore a better alternative. To test this, we conducted a meta-analysis of studies comparing
psychotherapy with pill placebo.
Method. Ten 10 studies comparing psychotherapies with pill placebo were identiﬁed. In total, 1240 patients were
included in these studies. For each study, Hedges’ g was calculated. Characteristics of the studies were extracted for
subgroup and meta-regression analyses.
Results. The effect of psychotherapy compared to pill placebo at post-test was g=0.25 [95% conﬁdence interval (CI)
0.14–0.36, I 2=0%, 95% CI 0–58]. This effect size corresponds to a number needed to treat (NNT) of 7.14 (95% CI
5.00–12.82). The psychotherapy conditions scored 2.66 points lower on the Hamilton Depression Rating Scale
(HAMD) than the placebo conditions, and 3.20 points lower on the Beck Depression Inventory (BDI). Some indications
for publication bias were found (two missing studies). We found no signiﬁcant differences between subgroups of the
studies and in meta-regression analyses we found no signiﬁcant association between baseline severity and effect size.
Conclusions. Although there are differences between the role of placebo in psychotherapy and pharmacotherapy
research, psychotherapy has an effect size that is comparable to that of antidepressant medications. Whether these effects
should be deemed clinically relevant remains open to debate.
Received 11 July 2012; Revised 1 February 2013; Accepted 5 February 2013
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Introduction
Comparisons of psychotherapy for depression versus
antidepressants have direct relevance to practice
guidelines and to policy issues concerning deployment
of clinical resources. Provision of medication and
psychotherapy require different clinician training and
skills and certiﬁcation and licensure. However, pre-
vious estimates of the efﬁcacy of antidepressants
relative to pill placebo conditions based on published
trials have been shown to be exaggerated because of
selective publication. Meta-analyses incorporating
data from both published and unpublished trials
obtained from the US Food and Drug Administration
(FDA) have yielded markedly lower estimates than
those based on published data alone (Melander et al.
2003; Turner et al. 2008). Although these meta-analyses
did not evaluate psychotherapy for depression, some
have drawn inferences about the relative efﬁcacy of anti-
depressants versuspsychotherapy. The claim is that anti-
depressants have clinically insigniﬁcant advantages
over pill placebo, and therefore alternative treatments
such as psychotherapy should be exhausted before turn-
ing to medication for depression (Kirsch et al. 2008).
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Turner et al. (2008) extracted data for 12 antidepress-
ants approved by the FDA between 1987 and 2004 and
compared the FDA’s regulatory decisions to what was
reported in the literature. According to the FDA ana-
lyses, only half of the trials were positive whereas,
according to the published literature, almost all of the
trials were positive. Studies that the FDA deemed posi-
tive were 12 times more likely to be published than
those deemed negative or questionable. The overall
effect size (mean standardized difference) for anti-
depressants relative to placebo was reduced from
0.41 to 0.31. Nonetheless, antidepressant/pill placebo
differences were statistically signiﬁcant for all medi-
cations. Kirsch et al. (2008) subsequently examined
FDA reviews for four of the 12 drugs examined by
Turner et al. (2008) and found essentially the same
effect size (0.32). However, Kirsch et al. (2008) applied
two criteria for clinical signiﬁcance proposed by
the National Institute for Clinical Excellence (NICE):
an effect size of 0.50 and an improvement on the
Hamilton Depression Rating Scale (HAMD; Hamilton,
1960) of 3 points. In so doing, they concluded that the
effects of antidepressants were clinically signiﬁcant
(though small) for severe depression but not clinically
signiﬁcant for mild to moderate levels of depression
(NICE, 2004). Although NICE no longer uses these cut-
offs as indicators of clinical relevance in its current
guideline, this judgment became the basis of Kirsch
et al.’s (2008) widely quoted claims to the general pub-
lic that patients who took a placebo would obtain an
effect almost as large as that obtained by taking an
antidepressant. These results have been interpreted
elsewhere to indicate that psychotherapy for de-
pression is preferable to antidepressants (Kirsch, 2009).
The Kirsch et al. (2008) study did not involve com-
paring psychotherapy for depression to pill placebo,
and comparisons between psychotherapy and pill
placebo control groups are controversial. The ascen-
dancy of the view that such comparisons are inappro-
priate for the evaluation of psychotherapy is reﬂected
in, and reinforced by, the small number of studies
allowing such a comparison. However, these psy-
chotherapy studies were designed to enable the evalu-
ation of an antidepressant condition versus pill placebo.
In the context of a clinical trial, it seems clear enough
why pill placebo should be contrasted with another
pill (the active medication being evaluated), but it is
less clear why pill placebo should be contrasted with
something that is not in a pill form, namely psycho-
therapy. The difference between a pill and psychother-
apy is obvious to both clinicians and patients, and this
unblinding allows potentially strong clinician and
patient preferences and expectations to come into
play. Several more common options for control con-
ditions exist, ranging from no treatment and waitlist
controls, which may also lead to unblinding, to com-
parison conditions that control for the effects of non-
speciﬁc and speciﬁc treatment factors, which may
limit unblinding of patients (Posternak & Zimmer-
man, 2007; Mohr et al. 2009).
However, there are arguments in favor of examining
the effect sizes of psychotherapy versus pill placebo
conditions, even while acknowledging these issues.
First, a pill placebo condition is more than the simple
administration of a pill, it involves active clinical man-
agement instilling positive expectations, and consider-
able support and attention. These aspects of a pill
placebo condition potentially control for the effects of
similar ingredients in the provision of psychotherapy
in a way that is not achieved with waitlist or no-
treatment conditions. Because it is clear to patients
assigned to such treatment conditions that they are
not receiving treatment, the associated effects would
be expected to be fairly small. Such small effects will
tend to inﬂate the difference between these conditions
and psychotherapy treatment conditions, thereby inﬂat-
ing the apparent effects of psychotherapy. If such com-
parisons are to be used, it seems warranted to include
pill placebo at least an auxiliary comparison.
However, the most compelling argument for a pill
placebo/psychotherapy comparison is pragmatic: the
efﬁcacy of psychotherapy versus antidepressants treat-
ment for depression has important clinical, policy and
economic implications. To compare the effects of two
treatment modalities, we should not compare the
effects of one to apples and the other to oranges.
Rather, the effects of the two modalities should be
compared to a common benchmark. One approach
would be to reassess the efﬁcacy of antidepressants
by contrasting them to waitlist or no-treatment control
conditions; however, because the design of such trials
would be open-label rather than double-blind, the
resulting effect sizes would probably be spuriously
inﬂated. The alternative approach is to compare both
treatment modalities to pill placebo. Although there
are ample efﬁcacy data on antidepressants compared
to pill placebo, there are relatively few data on psy-
chotherapy compared to pill placebo.
Another alternative would be to examine direct com-
parisons of the two treatments. Several meta-analyses
have examined these direct comparisons of psycho-
therapy and pharmacotherapy, and they typically
ﬁnd no signiﬁcant differences (Cuijpers et al. 2008b;
Imel et al. 2008). However, there is a persuasive
argument that head-to-head studies, involving two
active treatments, can be uninterpretable (Temple &
Ellenberg, 2000). The reason is that, in the absence
of placebo, there is no way of knowing whether the
two treatments are equally effective or equally ineffec-
tive. One example is a well-known trial comparing
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St John’s Wort to sertraline to placebo for depression
(Hypericum Depression Trial Study Group, 2002).
Ignoring the placebo, it could be concluded that
St John’s Wort performs about as well as sertraline,
hence it must be effective. Full response occurred
more often in patients treated with placebo than in
those treated with either active treatment. Hence,
even though comparative studies are informative,
comparisons with placebo remain important.
We therefore focus in this study on the efﬁcacy
of psychotherapy relative to pill placebo. Because pill
placebo more plausibly controls for positive expec-
tations, support and attention, it is conceivable that
this approach will lead to effect sizes that are smaller
than those historically found using waitlist and
no-treatment control conditions. This would have
important implications for clinical and policy decisions
concerning provision of psychotherapy versus anti-
depressants for depression. Because earlier research
based on head-to-head comparisons of psychotherapy
and pharmacotherapy have found that their effects on
depression are comparable (Cuijpers et al. 2008), our
hypothesis is that the effect size of psychotherapy is
comparable to that of pharmacotherapy, that is g=0.3
(Turner et al. 2008).
Method
Identiﬁcation and selection of studies
We used a database of 1344 papers on the psychologi-
cal treatment of depression that has been described in
detail elsewhere (Cuijpers et al. 2008), and that has
been used in a series of earlier published meta-analyses
(www.evidencebasedpsychotherapies.org). This data-
base is continuously updated through comprehen-
sive literature searches (from 1966 to January 2012).
In these searches we examined 13407 abstracts in
PubMed (3320 abstracts), PsycInfo (2710), EMBASE
(4389) and the Cochrane Central Register of Controlled
Trials (2988). These abstracts were identiﬁed by com-
bining terms indicative of psychological treatment
and depression (both MeSH terms and text words).
For this database, we also checked the primary studies
from 42 meta-analyses of psychological treatment for
depression to ensure that no published studies were
missed (www.evidencebasedpsychotherapies.org).
From the 13407 abstracts (9860 after removal of dupli-
cates), 1344 full-text papers were retrieved for possible
inclusion in the database.
We included trials that (a) were randomized, (b)
examined the effects of a psychological treatment and
(c) used pill placebo as a comparator, in patients who
were (d) adults and (e) diagnosed with a depressive
disorder. Studies that included participants with
co-morbid general medical or psychiatric disorders
were not used as an exclusion criterion. No language
restrictions were applied.
Quality assessment and data extraction
We assessed the validity of included studies using four
criteria of the Risk of Bias assessment tool, developed
by the Cochrane Collaboration (Higgins & Green,
2008). This tool assesses possible sources of bias in ran-
domized trials, including the adequate generation of
allocation sequence; the concealment of allocation to
conditions; the prevention of knowledge of the allo-
cated intervention (masking of assessors); and dealing
with incomplete outcome data (this was assessed as
positive when intention-to-treat analyses were con-
ducted, meaning that all randomized patients were in-
cluded in the analyses). Two other criteria of the Risk
of Bias assessment tool were not used in this study
because we found no clear indication in any of the
studies that these had inﬂuenced the validity of the
study (suggestions of selective outcome reporting; and
other problems that could put it at a high risk of bias).
In addition to indicators of study quality, we coded
several aspects of the included studies, including
the following participant characteristics: recruitment
method (community, from clinical samples, or other),
deﬁnition of depression (assessment with a diagnostic
interview or not), and target group (adults in general,
or more speciﬁc target groups such as older adults).
We also assessed the following intervention character-
istics: format (individual or group), number of ses-
sions, and the type of psychotherapy [cognitive
behavior therapy (CBT), interpersonal psychotherapy
(ITP), or other].
Because all studies reported the baseline score on the
HAMD, we also examined the effects of baseline sever-
ity by comparing randomized controlled trials (RCTs)
in which patients had a mean baseline HAMD<17,
reﬂecting mild depression, with RCTs in which
patients had a mean baseline of HAMD>18, reﬂecting
moderate (HAMD 18–24) or severe (HAMD>25)
depression (Katz et al. 1995). We also conducted a
meta-regression analysis with effect size as the depen-
dent variable and baseline severity (as the continuous
variable) as the predictor, to be consistent with pre-
vious research on the question of the effect of anti-
depressant medication as a function of initial severity
(Kirsch et al. 2008; Fournier et al. 2010). Data extraction
was conducted by two independent researchers.
Meta-analyses
For each comparison between a psychotherapy and a
pill placebo control group, the effect size indicating
the difference between the two groups at post-test
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was calculated (Hedges’ g or the standardized mean
difference). Effect sizes were calculated by subtracting
(at post-test) the average score of the psychotherapy
group from the average score of the placebo group,
and dividing the result by the pooled standard devi-
ation. Because several studies had relatively small
sample sizes, we corrected the effect size for small
sample bias according to the procedures suggested
by Hedges & Olkin (1985).
In the calculations of effect sizes, we only used those
instruments that explicitly measured symptoms of
depression, such as the Beck Depression Inventory
(BDI; Beck et al. 1961) or the HAMD (Hamilton,
1960). If more than one depression measure was
used, the mean of the effect sizes was calculated so
that each comparison yielded only one effect. If dichot-
omous outcomes were reported without means and
standard deviations, we used the procedures of the
Comprehensive Meta-Analysis software to calculate
the standardized mean difference. To calculate pooled
mean effect sizes, we used the Comprehensive
Meta-Analysis version 2.2.021. As we expected con-
siderable heterogeneity among the studies, we used a
random effects pooling model.
Because the standardized mean difference (Hedges’
g) is not easy to interpret from a clinical perspective,
we transformed these values into the NNT, using the
formulae provided by Kraemer & Kupfer (2006). The
NNT indicates the number of patients that have to be
treated to generate one additional positive outcome
(Laupacis et al. 1988).
As a test of homogeneity of effect sizes, we calcu-
lated the I2 statistic, which is an indicator of heterogen-
eity in percentages. A value of 0% indicates no
observed heterogeneity and larger values indicate
increasing heterogeneity, with 25% as low, 50% as
moderate and 75% as high heterogeneity (Higgins
et al. 2003). We calculated 95% conﬁdence intervals
(CIs) around I2 (Ioannidis et al. 2007), using the non-
central χ2-based approach within the heterogi module
for Stata (Orsini et al. 2005). We also calculated the Q
statistic, but only report whether this was signiﬁcant.
Subgroup analyses were conducted according to the
mixed effects model, in which studies within sub-
groups are pooled with the random effects model
whereas tests for signiﬁcant differences between sub-
groups are conducted with the ﬁxed effects model.
For continuous variables, we used meta-regression
analyses to test whether there was a signiﬁcant rela-
tionship between the continuous variable and effect
size, as indicated by a Z value and an associated p
value.
Publication bias was tested by inspecting the funnel
plot on primary outcome measures and by the
trim-and-ﬁll procedure of Duval & Tweedie (2000),
which yields an estimate of the effect size after the pub-
lication bias has been taken into account (as imple-
mented in Comprehensive Meta-Analysis version
2.2.021). We also conducted Egger’s test of the inter-
cept to quantify the bias captured by the funnel plot
and to test whether it was signiﬁcant. Furthermore,
we calculated the fail-safe N, which indicates the num-
ber of studies with an effect size of zero that cause the
resulting effect size to be non-signiﬁcant.
Power calculation
Because we expected only a limited number of studies,
we conducted a power calculation to examine how
many studies would have to be included to have sufﬁ-
cient statistical power to identify relevant effects. We
conducted a power calculation according to the pro-
cedures described by Borenstein et al. (2009).
First, we calculated how many studies are needed to
identify an effect size of 0.5, which has been proposed
as the threshold for a clinically relevant effect. These
calculations indicated that we would need to include
at least ﬁve studies with a mean sample size of 60
(30 participants for each condition) to be able to detect
an effect size of g=0.50 (conservatively assuming a
high level of between-study variance, τ2, a statistical
power of 0.80, and a signiﬁcance level, α, of 0.05).
Alternatively, we would need three studies with 80
participants each to detect an effect size of g=0.50.
Second, we calculated how many studies are needed
to identify an effect size of g=0.31, the effect size
found for pharmacotherapy versus placebo (Turner
et al. 2008). We found that we would need 11 studies
with a sample size of 60 (30 for each condition) or
nine studies with a sample size of 80 (40 for each con-
dition) to identify an effect size of g=0.31.
Results
Selection and inclusion of studies
After examining a total of 13407 abstracts (9860 after
removal of duplicates), we retrieved 1344 full-text
papers for further consideration. We excluded 1334
of the retrieved papers. The ﬂowchart describing the
inclusion process, including the reasons for exclusion,
is presented in Fig. 1. Ten of the 1344 retrieved full-text
papers included a comparison between a psychother-
apy and a pill placebo control group and were
included in this meta-analysis.
Characteristics of included studies
Selected characteristics of the included studies are pre-
sented in Table 1. A total of 1240 patients were
4 P. Cuijpers et al.
included in the 10 studies (668 in the psychotherapy
conditions and 572 in the placebo conditions).
Five studies recruited patients from clinical
samples, four studies recruited patients from the
community and one study used another recruitment
strategy. Seven studies were aimed at patients with
major depressive disorder (MDD), two studies were
aimed at patients with dysthymia or minor depres-
sion, and one study was aimed at patients with major
depression, dysthymia or minor depression. The
mean baseline severity was mild (HAMD<17) in
three studies, moderate (HAMD 18–24) in six stud-
ies and severe (HAMD>25) in one study (Katz et al.
1995).
In the 10 studies, 12 psychotherapies were compared
with a placebo condition (in each of two studies, two
different psychotherapies were compared with the
placebo condition). Four of the 12 psychotherapies
were cognitive behavior therapy, three were problem-
solving therapy, two ITP, another two were supportive
therapy, and one was behavioral activation therapy.
Eleven of the 12 psychotherapies used an individual
format, and one used a group format. The number of
treatment sessions ranged from six to 20. Patients in
all studies were randomized to a one of three con-
ditions (psychotherapy, medication or placebo), apart
from one study where there were more than three
conditions (Hegerl et al. 2010: CBT, medication, placebo,
patient preference arm, guided self-help control).
The quality of the included studies varied some-
what, but was generally high. All but one study
reported an adequate sequence generation. Six of the
10 studies reported allocation to conditions by an inde-
pendent (third) party. All 10 studies reported blinding
of outcome assessors and in nine of the 10 studies
intention-to-treat analyses were conducted. Six of the
10 studies met all four quality criteria, three met
three of four criteria; one study had a lower quality
(it met only one of the four criteria).
Effects of psychotherapy compared to pill placebo
control groups
The effect of psychotherapy compared to pill placebo
at post-test was g=0.25 (95% CI 0.14–0.36, I2=0%,
95% CI 0–58%). This effect size corresponds with an
NNT of 7.14 (95% CI 5.00–12.82). The effect sizes
and 95% CIs of each study are presented in Fig. 2
and separately for each type of psychotherapy in
Supplementary Table S1. A post-hoc power calculation
showed that the statistical power was 0.99.
We included two studies, each of which compared
two psychological treatments with a pill placebo
group (Elkin et al. 1989; Dimidjian et al. 2006). Thus,
13 407 references identified
by literature search:
- PubMed: 3320
- PsycINFO: 2710
- Embase: 4389
- Cochrane: 2988
After removal of duplicates:
9860 abstracts
1344 publications retrieved
10 randomized trials
comparing psychotherapies
with pill placebo
Excluded after reading title
and abstracts
Excluded: 1334
- Trials without relevant comparison (305)
-  Secondary papers on trials (242)
-  Studies with adolescents (69)
-  No random assignment (54)
-  Not only depression (165)
-  No psychotherapy (151)
-  No comparison condition (113)
-  Maintenance trial (53)
-  Other reason (182)
Fig. 1. Flowchart of inclusion of studies.
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Table 1. Selected characteristics of studies comparing psychotherapy for adult depression with pill placebo control groups
Study Recruitment
Target
group Diagnosis Conditions n Format nsessions Medication
a
Contact with
pharmacotherapist Country
Quality
SG CA BA ITT
Barber, 2011 Community Adults MDD (DSM-IV, SCID),
HAMD>14
1. Supportive 51 Individual 20 Sertraline Weekly/biweekly meetings with
psychopharmacologist
USA + − + +
2. Placebo 50
Barrett, 2001 Clinic Adults Dysthymia or minor
depression (DSM-III-R) +
HAMD>10
1. PST 80 Individual 6 Paroxetine Six treatment sessions of 10–15
min over 11 weeks
USA + + + +
2. Placebo 81
DeRubeis, 2005 Community Adults MDD (SCID, DSM-IV) 1. CBT 60 Individual 14 Paroxetine Weekly/biweekly meetings with
pharmacotherapist (20–45min)
USA + − + +
2. Placebo 60
Dimidjian,
2006
Community Adults MDD (DSM-IV)+BDI-II >
14+HAMD>17
1. CBT 38 Individual 16 Paroxetine Weekly/biweekly meetings with
pharmacotherapist (30–45min)
USA + − + +
2. Behavioral
activation
37
3. Placebo 41
Elkin, 1989 Clinic Adults MDD (RDC)+HAMD>14 1. CBT 59 Individual 16 Imipramine Weekly meetings with
pharmacotherapist (20–60min)
USA + + + +
2. IPT 61
3. Placebo 59
Hegerl, 2010 Clinic Adults Dysthymia, minor
depression or MDD+
HAMD score 8–22
1. CBT 59 Group 10 Sertraline Biweekly meetings with
psychiatrist
Germany + + + +
2. Placebo 61
Jarrett, 1999 Clinic Adults MDD with atypical
features (SCID,
DSM-III-R)
1. CBT 36 Individual 20 Sertraline Weekly meetings with
pharmacotherapist
USA + + + +
2. Placebo 36
Mynors-Wallis,
1995
Clinic Adults MDD (RDC)+HAMD>13 1. PST 30 Individual 6 Amitriptyline Six sessions of the same
duration as psychotherapy
UK + + + +
2. Placebo 30
Sloane, 1985 Other Older
adults
MDD 1. IPT 19 Individual 6 Nortriptyline N.R. USA − − + −
2. Placebo 14
Williams, 2000 Community Older
adults
Dysthymia or minor
depression (DSM-III-R) +
HAMD>10
1. PST 138 Individual 6 Paroxetine Six treatment sessions of
15min over 11 weeks
USA + + + +
2. Placebo 140
BA, Blinding of assessors; BDI, Beck Depression Inventory; CA, concealment of allocation to conditions; CBT, cognitive behavior therapy; HAMD, Hamilton Depression Rating
Scale; IPT, interpersonal psychotherapy; ITT, intention-to-treat analyses; MDD, major depressive disorder; PST, problem-solving therapy; RDC, research diagnostic criteria;
SG, adequate generation of allocation sequence; N.R., not reported.
a In all studies patients were randomized to one of three conditions: (1) psychotherapy, (2) medication or (3) placebo condition (only in the study from Hegerl et al. 2010 were
patients randomized to one of ﬁve conditions: CBT, medication, placebo, patient preference arm, guided self-help control).
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multiple comparisons from these studies were included
in the same analysis, while these comparisons are not
independent of each other. This may have resulted in
an artiﬁcial reduction in heterogeneity and may have
affected the pooled effect size. We examined the poss-
ible effects of this by conducting an analysis in which
we included only one effect size per study. First, we
included only the comparisons with the largest effect
size from these studies and then we conducted another
analysis in which we included only the smallest effect
sizes. As shown in Table 2, the resulting effect sizes
were almost the same as in the overall analyses.
We also calculated the effect sizes based on the
HAMD (while excluding effect sizes based on other
measurement instruments) and found comparable
results (g=0.34, 95% CI 0.21–0.46, I2=0, NNT=5.26,
95% CI 3.91–8.47). The psychotherapy conditions
scored 2.66 points lower on the HAMD than the pla-
cebo conditions (95% CI 1.62–3.71). The effect size
based exclusively on the BDI was also comparable
with the overall effect size (g=0.30, 95% CI 0.13–0.46,
I2=0, NNT=5.95, 95% CI 3.91–13.51). The psychother-
apy conditions scored 3.20 points lower on the BDI
than the placebo conditions (95% CI 1.35–5.04).
Inspection of the funnel plot and Duval & Tweedie’s
trim-and-ﬁll procedure indicated the presence of some
publication bias. After adjustment for missing studies,
the effect size dropped from g=0.25 to g=0.21 (95% CI
0.10–0.32, number of trimmed studies=2) and Egger’s
test did not indicate an asymmetric funnel plot (inter-
cept: 1.25, 95% CI 1.00–3.50, df 10, p=0.24). The fail-
safe N was 58, indicating that 58 studies with an effect
size of zero would have to be found to make the result
non-signiﬁcant.
Long-term follow-up effects were examined in only
three of the 10 studies (Elkin et al. 1989; Jarrett et al.
1999; Dimidjian et al. 2006), and because of this small
number of studies we decided not to examine these
further.
Subgroup and meta-regression analyses
We conducted a series of analyses to examine associ-
ations between characteristics of the studies and the
effect sizes.
One study delivered psychotherapy in group format
(Hegerl et al. 2010) whereas the other studies used an
individual format. In the same study, no formal diag-
nostic interview was used to establish the presence
of a depressive disorder. We examined whether
removal of this study resulted in a different mean effect
size. We found no indication that this study had an
effect on the mean effect size (after removal of this
study g=0.24, 95% CI 0.13–0.35, I2=0, NNT=7.46;
Table 2).
In one study, the randomization procedure was
unclear, and no intention-to-treat analyses were
reported, so the overall quality score for this study
was low. Removal of this study had little impact on
the overall outcomes (g=0.25, 95% CI 0.15–0.36, I2=0,
95% CI 0–60, NNT=7.14, 95% CI 5.00–11.90).
We conducted a series of subgroup analyses to
examine the association between study characteristics
and the effect size. We found no indication that the
effects size was signiﬁcantly associated with type of
psychotherapy, recruitment method (clinical samples
versus other), target group (adults in general versus
more speciﬁc target group), or whether the study
was aimed exclusively at patients with MDD or at
patients who might also have dysthymia, minor
depression or dysthymia. The results are summarized
in Table 2.
Finally, a meta-regression analysis with Hedges’ g as
the dependent variable did not indicate a signiﬁcant
g  95% CI 
Barber, 2011 0.06 –0.33 to 0.45
Barrett, 2001 –0.00 –0.31 to 0.31
DeRubeis, 2005 0.31 –0.05 to 0.67
Dimidjian, 2006 BA 0.24 –0.21 to 0.67
Dimidjian, 2006 CT 0.27 –0.17 to 0.71
Elkin, 1989 CBT 0.23 –0.12 to 0.59
Elkin, 1989 IPT 0.36 0.00 to 0.71
Hegerl, 2010 0.34 0.01 to 0.67
Jarrett, 1999 0.58 0.11 to 1.05
Mynors-Wallis, 1995 0.68 0.14 to 1.21
Sloane, 1985 0.08 –0.59 to 0.75
Williams, 2000 0.20 –0.03 to 0.44 
     Pooled 0.25 0.14 to 0.36
Hedges’ g and 95% CI
–0.50 0.00 0.50 1.00
Favours placebo Favours therapy
Fig. 2. Standardized effect sizes of psychotherapy for adult depression compared with control conditions: Hedges’ g.
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association between effect size and the number of ses-
sions in the psychotherapies (slope: 0.015, 95%
CI –0.007 to 0.038, p>0.1), nor did we ﬁnd an associ-
ation between effect size and baseline depression
severity according to the HAMD (slope: 0.016, 95%
CI –0.014 to 0.045, p>0.1). We also conducted a
meta-regression analysis with the number of sessions
with the pharmacotherapist in the placebo conditions
as predictor, but did not ﬁnd a signiﬁcant association
(slope: 0.005, 95% CI –0.019 to 0.029, p>0.1).
Discussion
A systematic search of the literature yielded only
10 studies comparing 12 psychotherapies for de-
pression to pill placebo. However, the ﬁnding of an
effect size equal to 0.25 was robust across speciﬁc
forms of therapies, and removal of any individual
trial. Focusing only on the HAMD, we obtained an
effect size of g=0.34, which, as hypothesized, was in
the range that Turner et al. (2008) and Kirsch et al.
(2008) obtained for antidepressants (effect size=0.32
and g=0.31 respectively).
Overall, when compared to pill placebo, psychother-
apy for depression was observed to have an effect size
well below the medium range (g=0.5), which some
researchers have recently used as a cut-off value for
clinical signiﬁcance, that is a virtual litmus test. It has
also been suggested that 3 points on the HAMD should
be regarded as a cut-off for clinical signiﬁcance.
Compared to pill placebo, psychotherapy reduced de-
pression by 2.66 points, which falls below this
3-point cut-off. Thus, if either of these cut-offs were
applied to the effect of psychotherapy, consistent
with the way others have applied them to the effect
of antidepressant medications (Kirsch et al. 2008;
Fournier et al. 2010), the conclusion would be that the
effect of psychotherapy is also clinically insigniﬁcant.
We would argue, however, that such a conclusion is
not valid because this reasoning begins with a ﬂawed
premise; these cut-offs were chosen arbitrarily and
without empirical evidence.
We also calculated the NNT, and found that one in
seven patients has to be treated with psychotherapy
to have one more successful outcomes than treatment
with placebo. For a potentially debilitating disorder
such as depression, some might consider this to be a
Table 2. Effects of psychotherapies compared with pill placebo control groups: Hedges’ ga
n g (95% CI) Z value I2b (95% CI) pc NNT (95% CI)
All studiess 12 0.25 (0.14–0.36) 4.59** 0 (0–58) 7.14 (5.00–12.82)
HAMD only 10 0.34 (0.21–0.46) 5.09** 0 (0–62) 5.26 (3.91–8.47)
BDI only 7 0.30 (0.13–0.46) 3.50** 0 (0–71) 5.95 (3.91–13.51)
One effect size per study (highest) 10 0.25 (0.14–0.37) 4.28** 0 (0–62) 7.14 (4.85–12.82)
One effect size per study (lowest) 10 0.24 (0.12–0.35) 4.02** 0 (0–62) 7.46 (5.10–14.71)
One study removed
Study without diagnosis removedc 11 0.24 (0.13–0.35) 4.17** 0 (0–60) 7.46 (5.10–13.51)
Low quality study removedd 11 0.25 (0.15–0.36) 4.61** 0 (0–60) 7.14 (5.00–11.90)
Subgroup analyses
Type of therapy
CBT 5 0.33 (0.16–0.50) 3.81** 0 (0–79) 0.23 5.43 (3.62–11.11)
Other therapy 7 0.20 (0.06–0.33) 2.84* 1 (0–71) 8.93 (5.26–29.41)
Recruitment
Clinical samples 6 0.31 (0.13–0.50) 3.30* 30.49 (0–72) 0.38 5.75 (3.62–13.51)
Other 5 0.21 (0.06–0.36) 2.71* 0 (0–75) 8.47 (5.00–29.41)
Target group
Adults in general 10 0.27 (0.15–0.39) 4.32** 0 (0–62) 0.55 6.58 (4.59–11.90)
Speciﬁc group 2 0.19 (–0.03 to 0.41) 1.67 N.S. 0 9.43e
HAMD, Hamilton Depression Rating Scale; BDI, Beck Depression Inventory; CBT, cognitive behavior therapy; CI, conﬁdence
interval; NNT, numbers needed to treat; N.S., not signiﬁcant (p>0.05).
a According to the random effects model.
b The p values indicate whether the difference between the effect sizes in the subgroups is signiﬁcant.
c This was also the only study in which psychotherapy was delivered in group format.
d This was also the only study in which the randomization procedure was unclear.
e The 95% CI was not calculated for this NNT because the lower limit was below zero.
* p<0.01, ** p<0.001.
8 P. Cuijpers et al.
clinically relevant outcome. However, what NNT
value should qualify as clinically relevant seems
open to debate.
There are several important differences between the
studies of psychotherapy for depression included in
our meta-analysis and the studies of antidepressants
included in the meta-analyses of Turner et al. (2008)
and Kirsch et al. (2008). The present meta-analysis
relied on published trials and did not allow for the
inclusion of both published and unpublished trials.
In the absence of an FDA-like repository of data,
how many trials are unpublished or which published
trials have been subjected to outcome reporting bias
cannot be known with certainty. Nevertheless, for psy-
chotherapy trials, there is ample statistical evidence of
publication bias (Cuijpers et al. 2010a) and strong
investigator allegiance effects (Luborsky et al. 1999).
The studies included in our meta-analysis were of
high quality, relative to much of the psychotherapy lit-
erature (Cuijpers et al. 2010b), resulting in a better esti-
mate of the true effect size.
It is impossible to blind comparisons of psychother-
apy to pill placebo. In such a situation, patient prefer-
ences may affect outcomes more than in comparisons
between antidepressants and pill placebo, although
the direction of this is not clear. Because most patients
prefer psychotherapy (Dwight-Johnson et al. 2000; van
Schaik et al. 2004), those who are randomized to their
preferred treatment may have better outcomes, which
may result in higher effect sizes. Moreover, not only
patients but also providers are not blinded as to
whether patients are assigned to psychotherapy or
pill placebo, and provider preferences may also affect
the outcomes in unknown ways. Whether these prefer-
ences indeed affect outcomes should be examined
in future research. It is also important to remember
that patients and providers were blinded for the psy-
chotherapy versus placebo conditions, but because
the studies also included a pharmacotherapy condition
they were blinded for the pharmacotherapy versus
placebo conditions. This may have had an inﬂuence
on the outcomes, although it is not clear which di-
rection such an inﬂuence may have had on our
outcomes.
Pill placebo groups are not inert conditions, and it is
not surprising therefore that the difference between
psychotherapy and pill placebo reported here is sub-
stantially smaller than the difference between psy-
chotherapy versus waitlist control or no treatment
(Cuijpers et al. 2008). Patients in pill placebo conditions
are provided with positive expectations and consider-
able encouragement and support that may be sufﬁcient
to produce improvement (Rief et al. 2009). In our
meta-analysis we found that there was frequent contact
between patients and pharmacotherapists in the pill
placebo conditions, and this may have made an impor-
tant contribution to the improvement of patients.
This study has several additional limitations. There
may have been a sampling bias because the included
studies compared psychotherapy with pharmacother-
apy, and patients with a strong preference for anti-
depressants or psychotherapy may have declined to
enroll in these trials altogether. This bias could limit
generalizability of these ﬁndings. Another important
limitation was the relatively small number of included
studies. Although we had sufﬁcient statistical power to
detect small effects and the quality of included studies
was relatively high, the power was limited for some of
the analyses, such as tests for subgroup differences and
for publication bias. We also limited the study to the
effects of acute treatments. There are indications, how-
ever, that the effects of psychological treatments last
longer than those of pharmacological treatments
(Hollon et al. 2005; David et al. 2008; Dobson et al.
2008). A ﬁnal limitation is that we considered psy-
chotherapy for depression as a monolithic treatment
whereas in fact several different treatments were
used in the included studies, such as CBT and IPT,
among others. We did ﬁnd a signiﬁcant effect for
CBT compared to placebo (p<0.01), but did not have
enough comparisons for other types of psychotherapy.
When other psychotherapies were compared directly
with one another, very little evidence for a differential
effect of different types of psychotherapies was found
(Cuijpers et al. 2008).
The results of this meta-analysis suggest that psy-
chotherapy for adult depression has an effect size
that is comparable to that of antidepressant medi-
cations when compared with placebo. Both fall below
the proposed cut-offs for clinical signiﬁcance.
Although some might question the clinical signiﬁcance
of both treatment modalities, we would instead ques-
tion the validity of the proposed cut-offs. Whether cut-
offs for clinical signiﬁcance should exist and, if they do,
what they should be are questions that, in our view,
remain unresolved.
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